Browse > Article

Minimal Stimulation using rhFSH and GnRH Antagonist for IVF Treated Patients of Advanced Age  

Kim, So-Ra (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Kim, Chung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Lee, Jin-Kyoung (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Jeon, Gyun-Ho (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Kim, Sung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Chae, Hee-Dong (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Kang, Byung-Moon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Publication Information
Clinical and Experimental Reproductive Medicine / v.36, no.1, 2009 , pp. 63-70 More about this Journal
Abstract
Objective: This study was performed to investigate the effectiveness of minimal stimulation using rhFSH and GnRH antagonist compared with GnRH antagonist multidose protocol (MDP) in IVF treated patients with aged 40 and above. Methods: Seventy-five patients with aged 40 and above were equally randomized to minimal stimulation group (n=37) or GnRH antagonist MDP group (n=38). For minimal stimulation group, ultrasound monitoring was started on cycle day 7 or 8. Daily injections of 0.25 mg cetrorelix together with 150 IU rhFSH were started from the day at 13${\sim}$14 mm of a leading follicle diameter. For GnRH antagonist MDP group, daily injections of 225 IU rhFSH were initiated from cycle day 2 and GnRH antagonist was started at a dose of 0.25 mg/day on rhFSH stimulation day 6 or the day at 13${\sim}$14 mm of leading follicle diameter. In both groups, transvaginal ultrasound-guided oocyte retrieval was performed. According to cleavage and morphologic characteristics of embryos, embryos were transferred 3 to 5 days after oocyte retrieval. Results: There were no differences in patients' characteristics and cycle cancellation rate between the two groups. Total dose and duration of rhFSH used were significantly fewer and shorter in minimal stimulation group than those in GnRH antagonist MDP group. The numbers of oocytes retrieved, mature oocytes and transferred embryos were also lower in minimal stimulation group. However, there were no significant differences in the clinical pregnancy rate and miscarriage rate between the two groups. Conclusions: This study demonstrates that minimal stimulation protocol provides comparable pregnancy rates to GnRH antagonist MDP with fewer dose and days of rhFSH used, and thus can be a cost-effective alternative in women aged 40 and above.
Keywords
Minimal stimulation protocol; Pregnancy rate; IVF; Advanced age;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Check JH, Peymer M, Lurie D. Effect of age on pregnancy outcome without assisted reproductive technology in women with elevated early follicular phase serum follicle-stimulating hormone levels. Gynecol Obstet Investig 1998; 45: 217-20   DOI   ScienceOn
2 Paulson RJ, Sauer MV, Lobo RA. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles:physiologic observation and preliminary experience. J Assist Reprod Genet 1994; 11: 28-32   DOI   ScienceOn
3 Biggers JD, Summers MC. When to avoid creating surplus human embryos. Hum Reprod 2004; 19: 2457-9   DOI   ScienceOn
4 Surrey E, Bower J, Hill D, Ramsey J, Surrey M. Clinical and endocrine effects of a microdose GnRH agonist flare regime administered to poor responders who are undergoing in vitro fertilization. Fetil Steril 1998; 69: 419-24   DOI   ScienceOn
5 Detti L, Williams D, Robins J, Maxwell R, Thomas M. A comparison of three down regulation approaches for poor responders undergoing in vitro fertilization. Fertil Steril 2005; 84: 1401-5   DOI   ScienceOn
6 Reyftmann L, Dechaud H, Loup V, Anahory T, Brunet-Joyeux C, Lacroix N, et al. Natural cycle in vitro fertilization cycle in poor responders. Gynecol Obstet Fertil 2007; 35: 352-8   DOI   ScienceOn
7 Gougeon A, Echochard R, Thalabard JC. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol Reprod 1994; 50: 653   DOI   ScienceOn
8 Maroulis GB. Effect of aging on fertility and pregnancy. Seminars Reprod Endocrinol 1991; 9: 165   DOI
9 Kim CH, Chae HD, Chang YS. Pyridostigmine cotreatment for controlled ovarian stimulation in low responders undergoing in-vitro fertilization embryo transfer. Fertil Steril 1999; 71:652-7   DOI   ScienceOn
10 Check JH. In vitro fertilization is expensive: when should a couple be advised to stop trying with their own gamates and week other options? Review of three cases. Clin Exp Obstet Gynecol 2008; 35: 5-9   PUBMED   ScienceOn
11 Elizur SE, Aslan D, Shulman A, Weisz B, Bider D, Dor J. Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF. J Assist Reprod Genet 2005; 22: 75-9   DOI   ScienceOn
12 Battaglia C, Salvatori M, Maxia N, Petraglia F, Facchinetti F, Volpe A. Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Hum Repod 1999; 14: 1690-7   DOI
13 Loutradis D, Drakakis P, Milingos S, et al. Alternative approaches in the management of poor response in controlled ovarian hyperstimulation. Ann N Y Acad Sci 2003; 997: 112-9   DOI   PUBMED   ScienceOn
14 Crosignani PG, Ragni G, Lombrosso GC, Scarduelli C, de Lauretis L, Caccamo A, et al. IVF: Induction of ovulation in poor responders. J Steroid Biochem 1989; 32: 171-3   DOI   ScienceOn
15 Surrey ES, Schoolcraft WB. Evaluation strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2007; 73: 667-76   DOI   ScienceOn
16 Ramsewak SS, Kumar A, Welsby R, Mowforth A, Lenton EA, Cooke ID. Is analgesia required for transvaginal single-follicle aspiration in in vitro fertilization? A double-blind study. J In Vitro Fert Embryo Transf 1990; 7: 103-6   DOI   ScienceOn
17 Casson PR, Lindsay EA, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000; 15: 2129-32   DOI   ScienceOn
18 Check JH, Chase J. Ovulation induction in hypergonadotropic amenorrhea with estrogen and human menopausal gonadotropin therapy. Fertile Steril 1984; 42: 919-22   DOI
19 Weghofer A, Margreiter M, Bassim S, Sevelda U, Beilhack E, Feichtinger W. Minimal stimulation using recombinant folliclestimulation hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil Steril 2004; 81:1002-6   DOI   ScienceOn
20 Check JH, Chase JS, Wu CH, Adelson HG. Ovulation induction and pregnancy with an estrogen-gonadotropin stimulation technique in a menopausal woman with marked hypoplasitc ovaries. Fertil Steril 1989; 160: 405-6
21 Karacan M, Erkan H, Karabulut O, Sarikamis B, Camlibel T, Benhabib M. Clinical pregnancy rates in an IVF program:Use of the flare-up protocol after failure with long regimens of GnRH-a. J Reprod Med 2001; 46: 485-9   PUBMED   ScienceOn
22 Keay SD, Lenton EA, Coole ID, Hull MGR, Jenkins JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotropins leading to a reduction in cycle cancellation rate in a standard IVF program. Hum Reprod 2001; 16: 1861-5   DOI   ScienceOn
23 Check JH, Katsoff B, Brasile D, Choe JK, Amui J. Pregnancy outcome following in vitro fertilization-embryo transfer (IVFET) in women of more advanced reproductive age with elevated serum follicle stimulating hormone (FSH) levels. Clin Exp Obstet Gynecol 2008; 35: 13-5   PUBMED   ScienceOn
24 Rongieres-Bertrand C, Olivennes F, Righini C, Fanchin R, Taieb J, Hamamah S. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotropin-releasing hormones antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14: 683-8   DOI   ScienceOn
25 Homburg R, Ostergard H. Clinical application of growth hormone for ovarian stimulation. Hum Reprod Update 1995; 1: 264-75   DOI   ScienceOn
26 Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Schoemaker J. In-vitro fertilization in a spontaneous cycle:easy, cheap and realistic. Hum Reprod 2000; 15: 314-8   DOI   ScienceOn